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Abstract
Background: Steroid hormone receptors (SHRs) are members of the superfamily of ligand-
activated transcription factors that regulate many biological processes. Co-regulators act as
bridging molecules between the SHR and general transcription factors to enhance transactivation
of target genes. Previous studies demonstrated that Stat3 is constitutively activated in prostate
cancer and can enhance prostate specific antigen (PSA) expression and promote androgen
independent growth. In this study, we investigate whether Stat3 can enhance steroid hormone
receptors activation.
Methods:  CV-1 cells in which plasmids expressing androgen receptor (AR), glucocorticoid
receptor (GR), progesterone receptor (PR) or estrogen receptor (ER) were cotransfected with a
constitutively active STAT3 mutant.
Results: Stat3 stimulates the transcriptional activity of all four SHR tested, AR, GR, PR and ER, in
a hormone-dependent manner. Stat3 acts in a synergistic fashion with other coactivators such as
SRC-1, pCAF, CBP, and TIF-2 on the transcriptional activity of these SHR. In addition, Stat3
significantly enhanced the sensitivity of androgen receptor in response to androgen. STAT3 did not
affect the specificity of AR for other steroid hormones other than androgen or binding of AR to
other hormone responsive elements.
Conclusions: These findings suggest that Stat3 can enhance the transactivation of AR, GR, PR and
ER, and activated Stat3 could have a role in the development or progression of a hypersensitive AR.
Introduction
Steroid hormone receptors (SHRs) are members of a fam-
ily of ligand-activated transcription factors that regulate
many biological processes, including metabolism, repro-
duction, and development. In the absence of ligand such
as androgen, glucocorticoid, progestin, and mineralocor-
ticoid, the SHR maintains a cytosolic inactive state by
association with heat shock proteins and/or other pro-
teins such as corepressors. Upon ligand binding, the SHR
undergoes conformational changes that involve releas e
from the repressor proteins, and translocation to the
nucleus where it can bind to specific hormone responsive
sequences in the DNA of genes regulated by steroid hor-
mones [1,2]. The mechanism by which SHRs affect the
rate of RNA polymerase II-directed transcription likely
involves the interaction of receptors with components of
the transcription preinitialization complex. This interac-
tion may be direct, or it may occur indirectly through the
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action of coactivators, which act as bridging factors. To
date, numerous coactivator molecules have been isolated
and characterized, encompassing several different families
[3,4]. Most of these cofactors are expressed in a wide vari-
ety of cell types and can interact with more than one type
of nuclear receptor. The recent findings that members of
the several different families of coactivators possess intrin-
sic histone acetyltransferase activity suggests that activated
SHRs, and nuclear receptors in general, may also recruit
these cofactors to remodel chromatin structure for better
accessibility of the transcriptional machinery to DNA
[5,6].
The JAK/STAT signaling pathway is involved in many
cytokines, hormones, and growth factors mediated signal-
ing pathways to regulate a variety of biological responses,
including development, cell differentiation, proliferation
and survival [7,8]. Once STAT proteins are activated by
tyrosine-phosphorylation, form homo or heterodimers
that are translocated to the nucleus, where they can bind
to specific sequences in the DNA, thereby stimulating
gene transcription. Similarly to nuclear receptors and to
other transcription factors, STAT proteins can interact
with coactivators to modulate their transcriptional activity
[9–12]. Other reports have shown direct interactions
between several members of the JAK/STAT signaling path-
way with SHRs [13–16]. Stat3 is one of the seven mem-
bers of the STAT family of proteins that has been shown
to modulate the expression of several genes related to con-
trol cell cycle, proliferation and apoptosis, such as Cyclin
D1, c-myc, and Bcl-xL, respectively [17]. Accordingly,
alterations in the activity of STAT3 have been associated
with cell transformation and cancer progression [18–20].
Prostate cancer is the most commonly diagnosed cancer,
and the second leading cause of death from cancer in
North American men. Prostate cells are dependant on
androgen to keep their normal functions. Activation of
androgen receptor (AR) in prostate cells is a key step in
developing and progression of prostate cancer. Most
patients respond initially to androgen deprivation or
antiandrogen regiments, but eventually the tumor
relapses in an androgen-independent stage with a poor
outcome. Several possible mechanisms have been sug-
gested to explain this activation of AR, including muta-
tions in the gene encoding AR that alter the specificity for
androgens, overexpression of the AR protein itself, cross-
talk to other signal transduction pathways, and altered
levels or activity of coactivators [21–23]. Several groups
including ours have demonstrated a role of activated Stat3
in the proliferation and survival of prostate cancer cells by
a mechanism that involves the AR [24–28].
In this study, we examined how Stat3 activates the SHRs
including AR. We studied whether Stat3, a transcription
factor itself, could act as a coactivator for AR and for other
SHRs. We report here that a constitutively active form of
Stat3 stimulates transcriptional activity of SHRs in a hor-
mone-dependent manner. We also report that active Stat3
can act synergistically with other coactivators to stimulate
SHRs transcriptional activity. Moreover, while Stat3 did
not affect specificity of AR to other steroid hormones
rather than androgen, or binding of AR to other HREs,
Stat3 significantly increased the sensitivity of AR to andro-
gen. These results can add more light to the mechanism by
which SHRs, and AR in particular, regulate gene
expression.
Results
Effect of Stat3 on AR-mediated transcriptional activity
Stat3 has been shown to enhance AR-mediated PSA
expression and AR transcriptional activity in prostate can-
cer cells [16,25,28]. We used two well-characterized
androgen-responsive luciferase reporter plasmids to study
the effect of Stat3 on AR-mediated transcriptional activity.
Both reporter plasmids contain several AREs that are
required for androgen induction. As comparison, we used
a saturating dose, 10 nM, of a synthetic androgen, R1881.
CV-1 cells do not express endogenous AR, therefore, all
experiments were performed in the presence of ectopic
wild-type human AR. CV-1 cells showed a strong response
to R1881 compared to vehicle-treated cells with both
androgen-responsive reporters used (Fig. 1). Cotransfec-
tion of a plasmid expressing a constitutively active mutant
Stat3, Stat3C, that forms homodimers and translocates to
the nucleus without tyrosine phosphorylation, affected
AR transcriptional activity in a dose-response manner
(Fig. 1A) but only in the presence of hormone (Fig. 1B and
1C). Constitutively activated Stat3 also activates another
androgen-responsive reporter contained the fragment -
286/+28 of the rat Probasin (PB) promoter (Fig. 1C).
Wild-type Stat3, that is in a latent cytosolic state without
tyrosine phosphorylation nor dimerization, showed no
additional stimulatory effect over the androgen-treated
cells (Fig. 1)
Effect of STAT3 on transcriptional activity of other SHRs
Having demonstrated that Stat3 enhance AR-mediated
gene transcription, we next investigated the role of Stat3
on transcriptional activation with other SHRs. For GR and
PR, we used the same reporter plasmid as for AR, ARE-
TATA-luciferase, since it shows promiscuous response to
all three SHRs [30]. For ER, we used ERE-TATA-luciferase
reporter that is specific for estrogen. CV-1 cells were also
cotransfected with plasmids expressing ectopically GR, PR
or ER. Like the AR, Stat3 enhances all three other SHRs
tested in the presence of the corresponding hormone (Dex
for GR, R5020 for PR, or E2  for ER) (Fig. 2). Taken
together, Stat3 enhances four different SHRs
transcriptional activity in the presence of theirNuclear Receptor 2003, 1 http://www.nuclear-receptor.com/content/1/1/3
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Figure 1
Active Stat3 stimulates androgen-induced AR tran-
scriptional activity. CV-1 cells were cotransfected with 
AR responsive reporter plasmids, ARE-TATA-luciferase (A, 
B) or PB(-286/+28)-luciferase (C), AR, and Stat3C, S tat3, or 
empty vector. After transfection, cells were treated for 36–
40 h with 10 nM R1881 or 0.1% ethanol as vehicle in 5% 
charcoal stripped serum in phenol red-free DMEM. Luci-
ferase activity was determined in cell extracts and corrected 
per µg of protein. Data are expressed as mean ± S.E. of three 
independent experiments.
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Figure 2
Active Stat3 stimulates hormone-induced transcrip-
tional activity of other SHRs. CV-1 cells were cotrans-
fected with specific luciferase reporter plasmids (ARE-TATA-
luciferase for GR and PR, and ERE-TATA-luciferase for ER), 
their corresponding SHR expressing plasmid (GR, top; PR, 
middle; and ER, bottom), and Stat3C plasmid or empty vec-
tor. After transfection, cells were treated for 36–40 h with 
10 nM of the corresponding hormone (Dex for GR; R5020 
for PR; and E2 for ER) or 0.1% ethanol as vehicle in 5% char-
coal stripped serum in phenol red-free DMEM. Luciferase 
activity was determined in cell extracts and corrected per µg 
of protein. Data are expressed as mean ± S.E. of three inde-
pendent experiments.
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corresponding ligand, suggesting that active Stat3 acts as a
coactivator for nuclear receptors.
We next compared the coactivator activity of Stat3 to that
of other known coactivators for AR. CV-1 cells were trans-
fected with the same amount (2 µg) of plasmid expressing
Stat3C, SRC-1, CBP/p300, TIF-2 or P/CAF, respectively.
Cells transfected with either coactivator or Stat3C showed
comparable and higher luciferase activity in response to
R1881 than cells treated with hormone alone in the pres-
ence of empty vector (Fig. 3). None of the coactivators
tested showed any luciferase activity in the absence of hor-
mone (data not shown). Stat3 is comparable to other
coactivators on AR transcriptional activity: SRC-1, CBP/
p300, TIF2, P/CAF.
It has been reported that coactivators in combination can
enhance transcriptional activity of SHRs compared to
when they are delivered to cells individually [29,30].
Recently, Giraud et al [12] reported a direct interaction of
Stat3 with SRC-1 and CBP/p300. We determined whether
Stat3 could act in a synergistic/additive way when admin-
istered to cells simultaneously to other coactivators. As
Fig. 3 shows, coexpression of active Stat3C simultane-
ously to SRC-1, CBP/p300, TIF-2 or P/CAF, resulted in a
more efficient enhancement of the reporter transcription
activity driven by AR as compared with any of the coacti-
vators expressed separately. A similar enhancement in
luciferase activity with simultaneous delivery of coactiva-
tors was observed with PR and ER (data not shown).
Stat3 did not affect the specificity of AR for non-androgen 
steroid hormones or non-AREs
Altered responses of AR include activation by non-andro-
gen ligands or recognition of other hormone responsive
elements different from AREs [22,23]. We studied if active
Stat3 could be responsible for this behavior of AR. CV-1
Figure 3
Active Stat3 stimulates AR transcriptional activity 
similarly as and synergistically with other coactiva-
tors. CV-1 cells were cotransfected with ARE-TATA-luci-
ferase, AR, and Stat3C or different coactivators (SRC-1, 
CBP/p300, TIF2 or P/CAF), individually or in combination. All 
wells contained the same total amount of DNA. After trans-
fection, cells were treated for 36–40 h with 10 nM R1881 or 
0.1% ethanol as vehicle in 5% charcoal stripped serum in phe-
nol red-free DMEM. Luciferase activity was determined in 
cell extracts and corrected per µg of protein. Data are 
expressed as mean ± S.E. of three independent experiments.
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Figure 4
Stat3 does not affect specificity of AR for non-andro-
gen steroid hormones or non-androgen responsive 
elements. (Top) CV-1 cells were cotransfected with ARE-
TATA-luciferase, AR, and Stat3C or empty vector, and 
treated for 36–40 h with 10 nM each different steroid hor-
mones (R1881, Dex, R5020, or E2) or 0.1% ethanol as vehicle 
in 5% charcoal stripped serum in phenol red-free DMEM. 
(Bottom) CV-1 cells were cotransfected with ARE-TATA-
luciferase (left) or ERE-TATA-luciferase (right), AR, and 
Stat3C or empty vector, and treated for 36–40 h with 10 nM 
R1881 or 0.1% ethanol as vehicle in 5% charcoal stripped 
serum in phenol red-free DMEM. Luciferase activity was 
determined in cell extracts and corrected per µg of protein. 
Data are expressed as mean ± S.E. of three independent 
experiments.
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cells were cotransfected with a reporter plasmid respon-
sive to androgen (ARE-TATA-luciferase) in the presence or
absence of AR and constitutively active Stat3C (Fig. 4 top)
and cells were treated with different steroid hormones.
Stat3C did not alter the specificity of AR for other steroid
hormones, since it showed transcriptional activity only in
response to androgen but not to Dex, R5020 or E2 (Fig 4,
top).
To test whether Stat3 could alter the specificity of AR to
other HREs, CV-1 cells were cotransfected with reporter
plasmids responsive to androgen (ARE-TATA-luciferase)
or to estrogen (ERE-TATA-luciferase), in the presence or
absence of AR and constitutively active Stat3C (Fig. 4 bot-
tom). With ARE-TATA-luciferase reporter, luciferase activ-
ity was dependent on the presence of AR and androgen,
without any effect of Stat3C on the basal levels of tran-
scription (Fig 4, bottom left). Stat3C did not modify the
sensitivity of AR for other hormone responsive elements,
since there was no response on the AR transcriptional
activity when we used an estrogen-specific responsive
reporter plasmid, ERE-TATA-luciferase (Fig 4, bottom
right).
Stat3 does not prevent inhibition of AR by the antiandro-
gen flutamide
Another altered response of AR is manifested in the so-
called "flutamide withdrawal syndrome" or more recently
broadened to "antiandrogen withdrawal syndrome". In
this condition, it is shown a decrease in serum levels of
PSA after removal of flutamide or other antiandrogens
from the treatment regiment [33]. We studied if active
Stat3 could be involved in this paradoxical effect of
antiandrogens. CV-1 cells cotransfected with an androgen
responsive reporter plasmid (ARE-TATA-luciferase), AR,
in the presence or absence of constitutively active Stat3C,
were treated with androgen and flutamide (Fig. 5). As
expected, flutamide blocked substantially the induction
of ARE-TATA-luciferase activity by R1881 in the absence
of active Stat3C. Similarly, the inhibitory effect of the
antiandrogen on AR was not prevented by the presence of
constitutively active Stat3C.
Stat3 affects sensitivity of AR for androgen
Other mechanism by which AR could show an altered
response results from an increase in its sensitivity to very
low levels of androgen [22,23]. We tested the role of active
Stat3 in this possibility cotransfecting CV-1 cells with an
androgen responsive reporter (ARE-TATA-luciferase), AR,
in the presence or in the absence of constitutively active
Stat3C. Cells were then treated with different doses of
androgen. Maximal transcriptional activity of AR was at 1
nM R1881 both in the presence and absence of Stat3C
(Fig. 6). Stat3C enhanced luci ferase activity driven by AR
even at the minimal dose of R1881 tested, 10 pM, which
showed no luciferase activity in the absence of Stat3C.
Discussion
Regulation of gene transcription mediated by hormone-
activated SHRs involves interaction with components of
Figure 5
Inhibition of AR transcriptional activity by flutamide 
is not blocked by active Stat3. CV-1 cells were cotrans-
fected with ARE-TATA-luciferase, AR, and Stat3C or empty 
vector, and treated for 36–40 h with 10 nM R1881 or 0.1% 
ethanol as vehicle in the presence or absence of 10 µM fluta-
mide, in 5% charcoal stripped serum in phenol red-free 
DMEM. Luciferase activity was determined in cell extracts 
and corrected per µg of protein. Data are representative of 
three independent experiments. Data are expressed as mean 
± S.E. of three independent experiments.
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Figure 6
Active Stat3 modifies the sensitivity of AR for andro-
gen. CV-1 cells were cotransfected with ARE-TATA-luci-
ferase, AR, and Stat3C (solid bars) or empty vector (empty 
bars), and treated for 36–40 h with different doses of R1881 
or 0.1% ethanol as vehicle, in 5% charcoal stripped serum in 
phenol red-free DMEM. Luciferase activity was determined in 
cell extracts and corrected per µg of protein. Data are 
expressed as mean ± S.E. of three independent experiments.
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the transcription complex. Coactivators are members of
the transcription complex, which act as bridging factors to
achieve optimal transcription activity. Coactivators are
probably present in the nucleus in preassembled multi-
complex units ready to associate to activated SHRs. The
role of the coactivators could be just as bridging factors,
although some of the members of the p160 family and
CBP/p300 present histone acetyltransferase activity
[34,35]. Stat3 is a member of the JAK/STAT signaling
pathway, which is a transcription factor itself that after
activation binds to specific sequences in DNA to regulate
expression of genes related to proliferation, differentia-
tion and cell survival. Constitutive activation of Stat3 has
been associated with cell transformation and cancer pro-
gression. Previous data including from our group showed
activation of AR in prostate cancer mediated by activation
of Stat3 [24–28].
Here we show that constitutively active Stat3 enhances
transcriptional activity of SHRs, AR, GR, PR, and ER, in a
comparable extent to the stimulation elicit by other coac-
tivators, and even more, in a synergistic manner to these
other coactivators. This stimulation is independent of the
DNA binding activity of Stat3, since none of the luciferase
reporters responsive to SHRs used throughout this report
contain the DNA sequence responsive to Stat3 [7]. We
cannot rule out, however, that Stat3 is affecting an inde-
pendent event that in turn activates SHR transcriptional
activity. Nevertheless, direct protein-protein interaction
has been documented by coimmunoprecipitation
experiments between Stat3 and AR [16,25], GR [13,14],
PR [36], and ER [37], suggesting that Stat3 might be
involved directly in transcriptional activity elicit by SHRs.
Moreover, Stat3 has also been directly associated with sev-
eral coactivators, such as SRC-1 and CBP/p300 [9,12].
Recruitment of coactivators to nuclear receptors takes
place via a common motif in the coactivators containing
a core consensus sequence LXXLL (L, leucine; X, any ami-
noacid) [38]. Most of the coactivators contain more than
one of these motifs, raising the question regarding specif-
icity of these motifs to specific activating domains in the
nuclear receptors. Stat3 also contains in its N-terminus
one of this motifs (221LAGLL225) [39]. Moreover, Stat3
also presents a Ser at -2 position of the LXXLL sequence,
which in the case of the coactivator TRBP defines selectiv-
ity for nuclear receptors [40]. Phosphorylation of Stat3
has been reported to occur only in 705Tyr and in 727Ser,
allowing dimerization and full transactivating activity
[41]. Whether this 219Ser next to the LXXLL motif is
involved in the coactivator activity of Stat3, and the inter-
action of Stat3 with other coactivators only takes place in
the context of Stat3 transcription factor activity or also can
be part of the general mechanism of the transcription
complex formation requires further studies.
Activation of AR is a driving force in development and
progression of prostate cancer. Several mechanisms could
be involved in this AR activation [21–23]. Changes in the
specificity of AR broadening the responsive spectrum to
other steroid hormones different to dihydrotestosterone,
can be caused by genetic mutations affecting different
regions of AR. We studied if active Stat3 could be suffi-
cient to alter the specificity of a wild-type AR to non-ster-
oid hormones. Our results indicate that native AR, with
no mutations, is responsible only to androgens, being
Stat3 not sufficient to alter this feature of AR. Activated
Stat3 d oes not affect the specificity of AR to bind to other
HREs different form ARE. Other altered response of
mutated AR is the paradoxical agonistic effect of antian-
drogens. Also in this case, Stat3 could not reverse the
antagonistic activity of flutamide on a wild-type AR. These
results point to mutations in AR as a necessary step in
some of the altered responses of AR seen in advanced
prostate cancer.
Another possible mechanism by which a prostate cancer
circumvents the low levels of androgens resulting from
androgen ablation therapy is by increasing the sensitivity
of AR to very low levels of androgens [42]. Stat3 increased
the sensitivity of AR to a dose of androgen that showed no
activity in the absence of Stat3, in the absence of a
mutated AR. The constitutive activation of Stat3 found in
prostate cancer [27,43] could be an initial step in the
clonal selection of malignant cells affecting not only
Stat3-regulated genes but also AR, as part of the transcrip-
tion complex recruited in response to activated AR.
Recently, overexpression of SRC-1 and TIF-2 has been
found in prostate cancer recurrence after androgen depri-
vation therapy [44], providing a molecular basis for AR
activation that could be similar to the one displayed by
Stat3 in its role as coactivator.
In conclusions, we report here that: 1) a constitutively
active form of Stat3 stimulates transcriptional activity of
SHRs in a hormone-dependent manner; 2) active Stat3
can act synergistically with other c oactivators to stimulate
SHRs transcriptional activity; 3) Stat3 did not affect specif-
icity of AR to other steroid hormones different than
androgen, or binding of AR to other HREs; 4) Stat3
increases the sensitivity of AR to androgen. These results
can help to elucidate the mechanism by which SHRs in
general, and AR in particular, regulate gene expression.
Methods
Plasmids
Luciferase reporter plasmids containing specific respon-
sive elements for AR, GR, and PR (GRE-TATA-luciferase)
and ER (ERE-TATA-luciferase) have been described else-
where [29,30]; another androgen-responsive reporter
contained the fragment -286/+28 of the rat Probasin (PB)Nuclear Receptor 2003, 1 http://www.nuclear-receptor.com/content/1/1/3
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promoter, and was obtained from Dr. R. Matusik,
Vanderbilt University, TN [31]. An expression plasmid for
wild-type hAR was kindly provided by Dr. C. Chang, Uni-
versity of Rochester, NY. Expression plasmids for hGR,
hPR α and ER have been also described [29,30]. Wild-type
inactive form of Stat3 (pCAGGS-HA-Stat3) was from Dr.
T. Hirano, Osaka University, Japan [32]. The plasmid
expressing a constitutively active form of Stat3 (Stat3C-
Flag) was obtained from Dr. J. Darnell, jr. [18]. This con-
stitutively activated Stat3 (a mutant produced by substitu-
tion of the cysteine residues within the COOH-terminal
loop of the SH2 domain of Stat3) induces cellular trans-
formation and tumor formation in nude mice [18]. The
plasmids to express other coactivators (SRC-1, CBP/p300,
TIF2 and PCAF) have been described elsewhere [29,30].
Cells and transfections
CV-1 cells were maintained in 10% fetal bovine serum
(Bio-Whittaker, Walkersville, MD), 100 u/ml penicillin,
100 µg/ml streptomycin in DMEM. Twenty four hours
before transfection, cells were plated in 12 well plates (1.2
× 105 per well) in 5% charcoal stripped serum (Hyclone,
Logan, UT), antibiotics, and 2 mM L-glutamine in phenol
red-free DMEM. For transfections, we used (per well) 0.2
µg reporter, 0.2 µg receptor, and 2 µg coactivator or empty
vector. In experiments studying synergy of coactivators,
the total amount of DNA was kept constant at 4.4 µg per
well. Transfections were performed with Superfect reagent
according to the manufacturer's protocol (Qiagen, Valen-
cia, CA). Three hours after transfection, medium was
removed and hormones added in phenol red-free DMEM
containing 5% charcoal stripped serum and antibiotics.
Dihydrotestosterone (DHT), dexamethasone (Dex), estra-
diol (E2), and the synthetic anti-androgen flutamide were
from Sigma (Saint Louis, MO). The synthetic analogs of
androgen and progesterone, R1881 and R5020, respec-
tively, were from New England Nuclear (Boston, MA).
Luciferase activity
Thirty six hours after incubation with hormones, luci-
ferase activity was determined in cell extracts according to
manufacturer's suggestions (Promega, Madison, WI).
Luciferase activity was normalized per µg protein, deter-
mined by Bradford assay (Coomasie Plus, Pierce, Rock-
ford, IL). Data are presented as a representative
experiment, which was independently repeated at least
three times.
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